Vistagen Therapeutics, INC Form 4 insider transactions

Director Joanne Curley reports receiving a grant of stock options for Vistagen Therapeutics, Inc.

Director Ann Michelle Cunningham acquired 14,100 stock options in Vistagen Therapeutics on September 6, 2024.

Mary L. Rotunno, a director at Vistagen Therapeutics, was granted stock options to purchase 14,100 shares of common stock on September 6, 2024.

Margaret M. FitzPatrick, a director of Vistagen Therapeutics, acquired stock options for 14,100 shares on September 6, 2024.

Joshua S. Prince, Chief Operating Officer of Vistagen Therapeutics, reports the acquisition of 2,671 shares of common stock through the company's Employee Stock Purchase Plan.

Cynthia Anderson, CFO of Vistagen Therapeutics, acquired 3,592 shares of common stock through the company's Employee Stock Purchase Plan on June 28, 2024.

Reid G. Adler, a Vistagen Therapeutics officer, reports acquiring 4,854 shares of common stock through the company's Employee Stock Purchase Plan.

CEO Shawn Singh reports purchasing and disposing of Vistagen Therapeutics (VTGN) stock on June 28, 2024, according to a Form 4 filing.

CEO of Vistagen Therapeutics, Shawn Singh, receives 500,000 stock options under the company's equity incentive plan.

Reid G. Adler, a Vistagen Therapeutics officer, reported the acquisition of 170,000 stock options on June 24, 2024.

Cynthia Anderson, CFO of Vistagen Therapeutics, reports the acquisition of 150,000 stock options.

Joshua S. Prince, Chief Operating Officer of Vistagen Therapeutics, was granted stock options for 150,000 shares on June 24, 2024, according to a Form 4 filing.

Mary L. Rotunno, a director at Vistagen Therapeutics, acquired 12,500 stock options on March 4, 2024, according to a Form 4 filing.

Director Jerry Gin acquired 12,500 stock options in Vistagen Therapeutics, Inc. on March 4, 2024, according to a Form 4 filing.

Margaret M. FitzPatrick, a director at Vistagen Therapeutics, was granted stock options for 12,500 shares on March 4, 2024.

Director Joanne Curley received 12,500 stock options in Vistagen Therapeutics, Inc.

Director Ann Michelle Cunningham of Vistagen Therapeutics, Inc. was granted stock options on March 4, 2024, according to a Form 4 filing with the SEC.

Director Jon Saxe of Vistagen Therapeutics, Inc. was granted stock options for 12,500 shares on March 4, 2024, according to a Form 4 filing.